Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial-Reference-Cited by-同舟云学术

Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial

Published:2010-01-02 Issue:1 Volume:24 Page:55-65
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Pozniak Anton L,Morales-Ramirez Javier,Katabira Elly,Steyn Dewald,Lupo Sergio H,Santoscoy Mario,Grinsztejn Beatriz,Ruxrungtham Kiat,Rimsky Laurence T,Vanveggel Simon,Boven Katia

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference19 articles.

1. Defining a molecular mechanism of synergy between nucleoside and nonnucleoside AIDS drugs;Basavapathruni;J Biol Chem,2004

2. Higher rates of viral suppression with nonnucleoside reverse transcriptase inhibitors compared to single protease inhibitors are not explained by better adherence;Weiser;HIV Clin Trials,2004

3. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an antiatherogenic lipid profile;van der Valk;AIDS,2001

4. The emerging roles of nonnucleoside reverse transcriptase inhibitors in antiretroviral therapy;Moyle;Drugs,2001

5. Class-sparing regimens for initial treatment of HIV-1 infection;Riddler;N Engl J Med,2008

Cited by 104 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Application of Nanomaterials in Biological and Biomedical Processes: Advances and Perspectives;Nanomaterials for Biomedical and Bioengineering Applications;2024

2. In Silico Pharmacokinetics Evaluation of Forgiveness for Doravirine and Rilpivirine;Therapeutic Drug Monitoring;2023-12-26

3. Observational cohort study of rilpivirine (RPV) utilization in Europe;AIDS Research and Therapy;2022-08-06

4. Antimicrobial agents and torsades de pointes;Torsades de Pointes;2022

5. Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical studies;Antiviral Therapy;2021-11